Ependymoma: Evaluation and Management Updates

[1]  T. Merchant,et al.  Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. , 2018, International journal of radiation oncology, biology, physics.

[2]  J. Jaremko,et al.  Value and Limitations of Diffusion-Weighted Imaging in Grading and Diagnosis of Pediatric Posterior Fossa Tumors , 2010, American Journal of Neuroradiology.

[3]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[4]  G. Reifenberger,et al.  EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.

[5]  T. Zhou,et al.  Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Scheithauer,et al.  Chemotherapy for Advanced CNS Ependymoma , 2004, Journal of Neuro-Oncology.

[7]  S. Khatua,et al.  Progression‐free survival of children with localized ependymoma treated with intensity‐modulated radiation therapy or proton‐beam radiation therapy , 2017, Cancer.

[8]  C. Hawkins,et al.  Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. , 2012, International journal of radiation oncology, biology, physics.

[9]  K. Aldape,et al.  cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors , 2020, Brain pathology.

[10]  Ryan A. Grant,et al.  Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database , 2016, Journal of Neuro-Oncology.

[11]  T. Merchant,et al.  Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.

[12]  R. Beroukhim,et al.  Myxopapillary ependymomas in children: imaging, treatment and outcomes , 2015, Journal of Neuro-Oncology.

[13]  Charmaine D. Wilson,et al.  A prognostic gene expression signature in infratentorial ependymoma , 2012, Acta Neuropathologica.

[14]  A. Brandes,et al.  A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia , 2005, Cancer.

[15]  M. Iqbal,et al.  An overview of the management of adult ependymomas with emphasis on relapsed disease. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  N. Tarbell,et al.  Proton Therapy for Pediatric Ependymoma: Mature Results from a Bicentric Study. , 2021, International journal of radiation oncology, biology, physics.

[17]  T. Pietsch,et al.  Pediatric ependymoma: an overview of a complex disease , 2021, Child's Nervous System.

[18]  Jun Yang,et al.  Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas , 2019, Neurosurgical Review.

[19]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[20]  D. Nam,et al.  Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  N. Tarbell,et al.  Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. Montes,et al.  Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas , 2010, Pediatric blood & cancer.

[23]  M. Preusser,et al.  Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. , 2015, Neuro-oncology.

[24]  O. Chinot,et al.  Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. , 2007, Brain : a journal of neurology.

[25]  J. Grill,et al.  High dose chemotherapy for childhood ependymona. , 1998, Journal of neuro-oncology.

[26]  D. de Ruysscher,et al.  Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. , 2016, International journal of radiation oncology, biology, physics.

[27]  P. Navarria,et al.  Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. , 2004, International journal of radiation oncology, biology, physics.

[28]  K. Aldape,et al.  High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma , 2020, Acta Neuropathologica Communications.

[29]  E. Bouffet,et al.  Chemotherapy for intracranial ependymomas , 1999, Child's Nervous System.

[30]  Grant W. Mallory,et al.  Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. , 2015, Neurosurgical focus.

[31]  Haifeng Chen,et al.  Risk factors for the recurrence of world health organization grade Ⅱ ependymomas of spinal cord in adults after microsurgical resections: A retrospective study of 118 patients in a single center , 2020, Clinical Neurology and Neurosurgery.

[32]  Dianqing Wu,et al.  Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. , 2020, Cancer cell.

[33]  S. Lam,et al.  Predictors of survival in patients with spinal ependymoma , 2015, Neurological research.

[34]  Mariella G. Filbin,et al.  Targeting fibroblast growth factor receptors to combat aggressive ependymoma , 2021, Acta Neuropathologica.

[35]  S. Zacharoulis,et al.  Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study , 2016, Journal of Neuro-Oncology.

[36]  D. Neuberg,et al.  A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer , 2013, Pediatric blood & cancer.

[37]  R. McLendon,et al.  Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. , 2021, Neuro-oncology.

[38]  C. Ames,et al.  Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. , 2013, Journal of neurosurgery. Spine.

[39]  D. Frappaz,et al.  Intracranial ependymomas in children: society of pediatric oncology experience with postoperative hyperfractionated local radiotherapy. , 2009, International journal of radiation oncology, biology, physics.

[40]  G. Tomei,et al.  Combined treatment of fourth ventricle ependymomas: report of 26 cases. , 2000, Surgical neurology.

[41]  S. Pfister,et al.  Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up , 2020, Neuro-Oncology.

[42]  A. Brandes,et al.  A multicenter study of the prognosis and treatment of adult brain ependymal tumors , 2004, Cancer.

[43]  C. Sommer,et al.  Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features , 2018, Brain pathology.

[44]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[45]  D. Indelicato,et al.  Surveillance imaging in pediatric ependymoma , 2020, Pediatric blood & cancer.

[46]  M. Snuderl,et al.  Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival , 2017, Journal of Neuro-Oncology.

[47]  R. Soffietti,et al.  Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. , 2016, Neuro-oncology.

[48]  D. Frappaz,et al.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Ivan,et al.  Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. , 2013, Neuro-oncology.

[50]  L. Kun,et al.  Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[51]  S. Sheth,et al.  Treatment trends and overall survival in patients with grade II/III ependymoma: The role of tumor grade and location , 2020, Clinical Neurology and Neurosurgery.

[52]  M. Milano,et al.  Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes , 2016, Journal of Neuro-Oncology.

[53]  M. Paglierani,et al.  O6- Methylguanine-DNA-Methyltransferase in Recurring Anaplastic Ependymomas: PCR and Immunohistochemistry , 2008, Journal of chemotherapy.

[54]  P. Ferroli,et al.  Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. , 2016, Neuro-oncology.

[55]  Y. Shibamoto,et al.  Postoperative Radiotherapy for Intracranial Ependymoma: Analysis of Prognostic Factors and Patterns of Failure , 2002, Journal of Neuro-Oncology.

[56]  T. Merchant,et al.  Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma , 2011, Journal of Neuro-Oncology.

[57]  M. Gilbert,et al.  Biology and management of ependymomas. , 2016, Neuro-oncology.

[58]  J. Villano,et al.  Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. , 2010, Journal of neurosurgery. Spine.

[59]  Richard G Grundy,et al.  Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. , 2007, The Lancet. Oncology.

[60]  Kristin L. Sainani,et al.  Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. , 2009, Journal of neurosurgery.

[61]  S. Khatua,et al.  Current therapy and the evolving molecular landscape of paediatric ependymoma. , 2017, European journal of cancer.

[62]  D. Frappaz,et al.  Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis , 2010, Child's Nervous System.

[63]  S. Terezakis,et al.  Clinical Investigation : Pediatric Cancer Management of Pediatric Myxopapillary Ependymoma : The Role of Adjuvant Radiation , 2013 .

[64]  M. Chamberlain,et al.  Temozolomide for recurrent intracranial supratentorial platinum‐refractory ependymoma , 2009, Cancer.

[65]  R. Gilbertson,et al.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Schild,et al.  In regard to the radiotherapy of myxopapillary ependymomas. , 2002, International journal of radiation oncology, biology, physics.

[67]  F. Tensaouti,et al.  Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[68]  Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients , 2021, Journal of Neuro-Oncology.

[69]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[70]  P. Sorensen,et al.  Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma , 2020, Nature Medicine.

[71]  M. Berger,et al.  Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy , 2011, Journal of Neuro-Oncology.

[72]  J. Finlay,et al.  Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial , 2013, Journal of Neuro-Oncology.

[73]  A. J. Barkovich,et al.  Imaging of ependymomas: MRI and CT , 2009, Child's Nervous System.

[74]  Diane D. Liu,et al.  An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) , 2015, Journal of Neuro-Oncology.

[75]  M. Gilbert,et al.  Ependymomas of the adult: molecular biology and treatment , 2008, Current opinion in neurology.

[76]  A. Wade,et al.  Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? , 2001, Journal of neurosurgery.

[77]  L. Junck,et al.  Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. , 2016, Journal of neurosurgery.

[78]  A. Eggert,et al.  Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice , 2015, Cancer Immunology, Immunotherapy.

[79]  Chemotherapy for intracranial ependymoma in adults , 2016, BMC Cancer.

[80]  D. Kondziolka,et al.  Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. , 2010, Journal of neurosurgery. Pediatrics.

[81]  T. Mikkelsen,et al.  Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System , 2013, Brain pathology.

[82]  N. Stence,et al.  Fractionated stereotactic radiosurgery for recurrent ependymoma in children , 2013, Journal of Neuro-Oncology.

[83]  S. Pfister,et al.  Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. , 2020, Neuro-oncology.

[84]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[85]  M. Berger,et al.  Phase II study of pre‐irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology Group , 2012, Pediatric blood & cancer.

[86]  J. Kilday,et al.  Pediatric ependymomas: destined to recur? , 2021, Neuro-oncology.

[87]  C. Wetmore,et al.  Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021 , 2016, Cancer medicine.

[88]  P. Grigsby,et al.  Postoperative radiation therapy for grade II and III intracranial ependymoma. , 2005, International journal of radiation oncology, biology, physics.

[89]  O. Chinot,et al.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. , 2010, Neuro-oncology.

[90]  T. Pietsch,et al.  Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. , 2015, Neuro-oncology.

[91]  P. Péran,et al.  Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. , 2016, The British journal of radiology.

[92]  R. Goldbrunner,et al.  Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome , 2010, Acta Neurochirurgica.

[93]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. , 2020, Neuro-oncology.

[94]  P. Brown,et al.  Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis , 2013, Journal of Neuro-Oncology.

[95]  T. Jaspan,et al.  Assessing ‘second-look’ tumour resectability in childhood posterior fossa ependymoma—a centralised review panel and staging tool for future studies , 2016, Child's Nervous System.

[96]  T. Mikkelsen,et al.  AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL , 2014 .

[97]  I. Sardi,et al.  Second-look surgery for ependymoma: the Italian experience. , 2011, Journal of neurosurgery. Pediatrics.

[98]  M. Gilbert,et al.  Ependymomas in Adults , 2010, Current neurology and neuroscience reports.

[99]  Douglas C. Miller,et al.  Ependymomas , 2013 .

[100]  P. Allen,et al.  Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center , 2006, Journal of Neuro-Oncology.

[101]  R. Stupp,et al.  Bevacizumab for recurrent ependymoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  A. Raghunathan,et al.  Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. , 2019, Journal of neuropathology and experimental neurology.

[103]  K. Ichimura,et al.  Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression , 2016, Pediatric blood & cancer.